Status:
UNKNOWN
Concurrent Paclitaxel and Radiotherapy After Adjuvant Doxorubicin and Cyclophosphamide for Stage 2 or 3 Breast Cancer
Lead Sponsor:
Assiut University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The aim of this study is Evaluation of the efficacy \& toxicity of concurrent paclitaxel and breast radiotherapy and assesment of overall survival \& progression free survival
Detailed Description
Over the recent years , breast cancer remains the most common cancer in women in the world . With nearly 107 Million new Cases diagnosed in 2012 (second most common cancer over all) . this represent a...
Eligibility Criteria
Inclusion
- Inclusion criteria :
- • This study will include women aged 18 years \&older.
- patients must be histologically diagnosed with breast cancer (ductal \& others).
- patients who underwent conservative breast surgery \& modified radical mastectomy.
- patients with stage ll\&lll breast cancer.
- patients who received (AC) as adjuvant treatment .
- Exclusion Criteria:
- patients with stage 1 or 4 breast cancer.
- patients received adjuvant chemotherapy rather than (AC) .
- patients with prior irradiation with thoracic region .
- pregnancy or lactation .
- patient with serious comorbid disease such as chronic obstructive pulmonary disease .
Exclusion
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04809844
Start Date
September 1 2023
End Date
December 1 2023
Last Update
October 18 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.